Lit­tle Leo Phar­ma en­ters the prize-fight ring with pos­i­tive PhI­II atopic der­mati­tis da­ta. Now they just have to beat Dupix­ent

A day af­ter new Sanofi CEO Paul Hud­son staked his rep­u­ta­tion and the fu­ture of the phar­ma gi­ant on mak­ing Dupix­ent a mega­suc­cess sto­ry, lit­tle Leo Phar­ma is throw­ing down the gaunt­let on atopic der­mati­tis.

Three years ago Leo paid As­traZeneca $115 mil­lion to buy up rights to use tralok­inum­ab against atopic der­mati­tis — with $1 bil­lion more on the ta­ble in mile­stones — the Dan­ish com­pa­ny says their drug has swept up pos­i­tive re­sults for all pri­ma­ry and sec­ondary end­points in three Phase III tri­als. Now they plan to start the fi­nal push for reg­u­la­to­ry ap­provals so they can chal­lenge the heavy­weight cham­pi­ons in this slugfest.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER